← All chemicals

CAS 680-31-9

Hexamethylphosphoramide (HMPA)

organophosphorus solventcarcinogenHAP

Hexamethylphosphoramide (HMPA) is a powerful polar aprotic solvent widely used in organic chemistry laboratories for difficult reactions — a carcinogen that is commonplace in synthetic chemistry but whose well-characterized nasal cavity tumorigenicity in rodents after inhalation exposure has led to strict laboratory handling requirements that are often inadequately followed.

Where It Comes From

HMPA was introduced as a laboratory solvent in the 1960s and quickly became valued for its ability to facilitate difficult nucleophilic substitutions, dissolve difficult organolithium reagents, and enable novel reaction conditions in organic synthesis [1]. The hexamethyl phosphoramide group's strong coordination to metal cations (lithium, magnesium) sequesters them efficiently, enhancing the reactivity of organometallic reagents [2]. By the 1970s, inhalation studies in rats showed dramatic induction of nasal cavity squamous cell carcinomas at relatively low concentrations — this finding triggered OSHA and academic laboratory community concerns about its widespread uncontrolled use in research settings [1]. Unlike many industrial chemicals, HMPA's primary exposure context is university and industrial research laboratories performing organic synthesis [2].

How You Are Exposed

The primary exposure is inhalation by organic chemists using HMPA as a solvent in reactions performed outside of adequately ventilated chemical fume hoods [1]. Skin contact and inhalation during reactions involving HMPA-enhanced organolithium chemistry, anionic polymerization, or S N 2 reactions are the typical exposure scenarios [2]. Because HMPA is not volatile at room temperature (bp 232°C), vapor levels during use can be deceivingly low, leading to inadequate precautions during longer or heated reactions [1].

Why It Matters

HMPA is metabolized to trimethylphosphoric acid and trimethylamine via demethylation — reactive metabolites that alkylate DNA and proteins [1]. Nasal cavity squamous cell carcinomas were induced in rats at exposure concentrations achievable during bench chemistry — a finding corroborated by the nasal cavity as the first site of inhalation exposure to heavy, low-volatility vapors [2]. EPA and IARC classify HMPA as a Group 2B possible human carcinogen [1].

Who Is at Risk

Organic chemists in academic and industrial research laboratories [1]. There is no community exposure pathway [2].

How to Lower Your Exposure

1. All reactions using HMPA must be performed inside a certified chemical fume hood — vapor generation increases with temperature [1]. 2. Consider alternative co-solvents — N-methylpyrrolidone (NMP), DMPU, or DMSO can substitute for HMPA in many reactions [2]. 3. Minimize HMPA volume used; dispose as hazardous waste [1].

References

  1. [1]IARC (1999). Monographs Volume 71: HMPA. https://monographs.iarc.fr/
  2. [2]EPA IRIS: Hexamethylphosphoramide. https://iris.epa.gov/

Recovery & Clinical Information

Body Half-Life

HMPA is metabolized relatively quickly — blood half-life approximately 2-6 hours [1]. Urinary trimethylphosphoric acid for monitoring [2].

Testing & Biomarkers

No clinical biomarker [1]. Urinary metabolites for research studies [2].

Interventions

Remove from exposure [1]. No antidote [2].

Recovery Timeline

Blood levels clear within hours [1].

Recovery References

  1. [1]IARC (1999). Monographs Volume 71. https://monographs.iarc.fr/
  2. [2]NIOSH HMPA guidance. https://www.cdc.gov/niosh/

Track your exposure to Hexamethylphosphoramide (HMPA)

Pollution Profile maps your lifetime exposure history to EPA-tracked chemicals.

Get early access

We use cookies and analytics to understand how people use Pollution Profile and improve the experience. We never sell your data. Learn more.